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Background:  Individuals with type O blood are more likely to have reduced factor VIII and von Willebrand factor 
levels compared to their non-O counterparts.  Hydroxyethyl starch (HES), which is widely used for blood volume 
replacement, can induce coagulopathy.  Therefore, we tested whether blood type O patients show more coagulopathy 
and blood loss than non-O patients after infusion of 6% HES. 
Methods:  Thirty-four non-O and 20 type O patients scheduled for posterior lumbar interbody fusion (PLIF) involving 
3 vertebrae or less from June 2007 to August 2008 were enrolled.  Fifteen ml/kg of 6% HES was administered during 
the operation.  Coagulation profiles was checked at pre-infusion (T0), 5 min after the end of infusion (T1), 3 hr after 
the end of infusion (T2), and 24 hr after the end of infusion (T3). Bleeding was measured during and after surgery for 
24 hours.
Results:  Baseline factor VIII concentration was lower and aPTT was longer in type O patients compared to those 
of non-O patients. 6% HES infusion decreased most of the coagulation factors at T1 in both groups, which were 
recovered in a time dependent manner.  Factor VIII and aPTT of blood type O patients fell off the normal range at T1.   
However, other coagulation factors, thromboelastography variables, and blood loss were not different between the 
groups. 
Conclusions:  Despite inborn low factor VIII which further decreased shortly after HES infusion, blood type O 
patients did not show more blood loss than non-O blood type after 15 ml/kg of HES infusion in PLIF surgery.  (Korean 
J Anesthesiol 2010; 58: 344-350)
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Introduction
    Posterior lumbar interbody fusion (PLIF) is usually conducted 
in elderly patients and continuous bone bleeding and oozing 
throughout the operation is a frequent finding. Instead of rapid 
infusion of large amount of crystalloid solutions which can 
be a burden to elderly patients with limited cardiovascular 
reserve, hydroxyethyl starch (HES) is commonly used to replace 
intravascular volume for PLIF. 
    Hydroxyethyl starch (HES), a synthetic colloid, readily allows 
a 1 : 1 replacement and remains longer in the intravascular 
space compared with crystalloid solutions [1]. However, HES 
can induce coagulopathy due to inhibition of endothelial cell 
activation [2], reduced release of factor VIII/von Willebrand 
factor (VWF) [3], and impairment of platelet function and fibrin 
polymerization [4,5]. Individuals with type O blood are reported 
to have an increased risk of spontaneous skin and mucous 
membrane hemorrhage [6] and lower amounts of circulating 
factor VIII/VWF than patients with other blood types [7-10]. 
Therefore, the possibility of coagulopathy and aggravated bone 
bleeding and oozing in O blood type patients by HES infusion 
could have an important implication in PLIF. 
    In the present research, we studied the difference in coagu-
lation and bleeding between the O and non-O blood types after 
infusion of 15 ml/kg of 6% HES to patients undergoing posterior 
lumbar interbody fusion (PLIF) involving 3 vertebrae or less. 
We hypothesized that blood type O patients would show more 
coagulopathy and blood loss after HES infusion than non-O 
blood types in PLIF. 
    In addition, we followed the coagulation profile for 24 h after 
HES infusion to determine how long its effects are sustained.
Materials and Methods
    This prospective study was approved by the Institute of 
Research Board of our hospital and written informed consent 
was obtained from all patients. All cases of PLIF of three 
vertebrae or less from June 2007 to August 2008 were subjected 
to the study. Exclusion criteria were patient’s refusal, American 
Society of Anesthesiologist Physical Status (ASA) 3 or 4, pre-
vious back surgery, the presence of cardiovascular disease, 
cerebral vascular disease, hepatic, pulmonary, or renal disease, 
hemoglobin <12 g/dl, platelet count <150 × 10
3/μl, coagu-
lopathy, taking medications likely to alter coagulation less than 
2 weeks before the study. Finally, 34 non-O and 20 O blood type 
patients were enrolled.
    No patient received premedication. Intraoperative monitoring 
included a three lead electrocardiogram, non-invasive and inva-
sive arterial pressures, pulse oximetry, expired CO2, oropha-
ryngeal temperature, and urine output. Tracheas were intu-
bated after administering thiopental sodium (3 to 5 mg/kg) 
and rocuronium (0.6 mg/kg). An arterial line, a 16 G peripheral 
line, and a Foley catheter were catheterized and secured after 
anesthesia induction. Anesthesia was maintained with inhaled 
sevoflurane (1.0-2.5 vol%) in a mixture of oxygen and air (50% : 
50%) and continuous infusion of remifentanil (0.02-0.25 μg/
kg/min) to maintain blood pressure and heart rate within 20% 
of baseline values. 
    Fifteen ml/kg of 37
oC Voluven (Voluven
Ⓡ, Fresenius Kabi, 
Germany) was infused via the 16G peripheral line at a rate of 10 
ml/kg/hr using blood warmer (Flotem, HanKook Vaccine inc., 
Korea) from the start of subperiosteal dissection. Crystalloid 
was administered at a rate of 10 ml/kg/h. 
    Blood sampling was performed for coagulation profile and 
hematocrit before colloid infusion (T0), 5 minutes after the 
end of infusion (T1), 3 hours after the end of infusion (T2), and 
24 hours after the end of infusion (T3). Thromboelastography 
(TEG) was checked at T0, T1 and T2. Blood samples were drawn 
using arterial lines after removing 10 ml of blood to prevent 
heparin contamination. Blood was collected into Vacutainer 
tubes (Vacutainer
TM, Becton Dickinson, USA) containing 0.129 
mol/L of trisodium citrate for coagulation tests. Factor VIII 
activity was measured using an automated coagulation analyzer 
(STA-R evolution
Ⓡ, Diagnostica Stago, France) with aPTT reagent 
(C.K Prest, Diagnostica Stago, France) and factor VIII-deficient 
plasma (Diagnostica Stago, France). An Enzyme-Linked Im-
mu  no  fluorescence Assay was used for VWF : Ag on a VIDAS 
(Bio  Merieux, France) with VWF : Ag
Ⓡ reagent (BioMerieux, 
France). TEG
Ⓡ tracings were obtained from whole blood on a 
Thrombelastograph 3.000 C
TM (Haemoscope Corp, USA). TEG 
provides global information on the entire coagulation process 
and measures the viscoelastic properties of blood in vitro [11]. 
In the components of TEG, reaction time (r) means initial fibrin 
formation, coagulation time (k) means fibrin formation velocity, 
the alpha angle indicates the rapidity of fibrin buildup, maximal 
amplitude (MA) indicates the strength of the fibrin clot. The 
coagulation index (CI) represents the overall coagulation status, 
and is calculated as CI = -0.1227r + 0.0092k + 0.1655MA - 
0.0241 alpha angle - 7.7922 [12]. 
    Bleeding was measured during and after surgery for 24 hours; 
Intraoperative estimated blood loss = (volume in the suction 
bottle - amount of irrigation fluid) + amount of blood on the 
surgical field and drape + amount of blood on surgical pads [fully 
soaked: 20 ml, half soaked: 10 ml]. Postoperative blood loss = 
amount of blood drainage in the postanesthesia care unit and 
ward. 
    Patients were transfused if their hematocrit fell to 24%. Fresh 
frozen plasma transfusion was indicated when the International 
Normalized Ratio (INR) was >2.0 or cryoprecipitate when fibri-
n  ogen levels were <100 mg/dl.346 www.ekja.org
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Statistical analysis
    The primary outcome variable was the difference in the amount 
of blood loss during and for 24 hours of operation between the 
non-O and O groups. The expected differences in means were 
set at 300 ml with an expected standard deviation of 300 ml. A 
sample size of 17 in each group was required to achieve a power 
of 80% with an alpha error of 0.05. Student’s t-test or the Mann-
Whitney Test was used depending on the normality of the data. 
For comparisons before and after colloid infusion, we used one-
way repeated measures analysis of variance with Holm-Sidak 
post hoc tests. All P values were two tailed, and a P value < 0.05 
was considered significant.
Results
    No patients were excluded due to protocol violation and none 
received fresh frozen plasma or cryoprecipitate during the study 
period. 
    There was no difference in demographic and operative profiles 
between the non-O and O groups. The amount of crystalloid 
and HES administered during operation was similar between 
the two groups (Table 1). 
    Factor VIII was lower in the O group compared to the non-O 
group before HES infusion and throughout the study period 
(P < 0.05) (Fig. 1). The time dependent changes of factor VIII 
after HES infusion were similar for both groups. Factor VIII 
decreased at T1 in both groups, which made factor VIII fall 
off the normal range in the O group. However, factor VIII was 
increased more than the value of T0 at T2 and T3 in both groups 
(Table 2). The magnitude of decrease of factor VIII at T1 was not 
different between the groups (decreased proportion of factor 
VIII at T1: non-O group 19.6 ± 21.3% vs. O group 24.9 ± 27.1%, 
P > 0.05) and correlated with the magnitude of decrease of 
Fig. 1. Factor VIII was lower in the O group compared to the non-O 
group before HES infusion and throughout the study period. T0: pre-
infusion, T1: 5 min after infusion, T2: 3 hr after infusion, T3: 24 hr 
after the end of infusion. *P < 0.05 between Non-O and O groups. 
Error bars are SD.
Table 1. Demographic Data
Non-O 
(n = 34)
O
(n = 20)
Sex (M/F)
ASA (1/2)
Age (yr)
Weight (kg)
Height (cm)
OP
    Vertebrae (1/2/3)
    Mean 
Duration of operation (min)
Crystalloid (ml)
HES (ml)
11/23
11/23
58.7 ± 10.5
66.2 ± 10.9
160.4 ± 7.8
13/19/2
1.7 ± 0.6
228 ± 61
2,344 ± 850
962 ± 145
11/9
11/9
  58.5 ± 10.1
66.3 ± 9.7
161.0 ± 10.2
8/10/2
  1.7 ± 0.7
223 ± 82
  2,493 ± 1,417
  964 ± 145
Values are mean ± SD. There were no differences between the non-
O and O groups. OP: posterior lumbar interbody fusion. Vertebrae: 
number of operated vertebrae, Mean: mean number of operated ver-
tebrae. HES: hydroxyethyl starch. 
Table 2. Coagulation
Non-O O
Normal range T0 T1 T2 T3 T0 T1 T2 T3
Hematocrit (%)
PLT (×10
3/µl)
PT (INR)
aPTT (sec)
Fibrinogen (mg/dl)
VWF: ag (%)
Factor VIII (%)
31.8-43.8
141-316
0.9-1.1
32.0-41.2
182-380
  50-150
  60-150
36.7 ± 4.1
 153 ± 33
†
  1.3 ± 1.7
34.6 ± 2.8
 253 ± 56
§
 119 ± 52
 111 ± 30
29.8 ± 4.5
 124 ± 24
  1.2 ± 0.1
38.9 ± 3.9
‡
 183 ± 27
 112 ± 57
   86 ± 38**
28.9 ± 5.0
 127 ± 33
  1.2 ± 0.1
34.7 ± 4.4
 177 ± 30
 124 ± 53
1 53 ± 57
† †
28.7 ± 4.3
 124 ± 28
  1.2 ± 0.1
37.7 ± 4.0
‡
 269 ± 53
||
 141 ± 55
 150 ± 47
† †
37.5 ± 2.8
 150 ± 40
†
  1.1 ± 0.1
36.6 ± 2.8*
 263 ± 68
§
 111 ± 48
   78 ± 25*
30.0 ± 5.1
 135 ± 46
  1.2 ± 0.1
41.1 ± 4.2*,‡
 182 ± 33
 102 ± 42
   58 ± 26*,**
31.1 ± 2.4
 119 ± 34
  1.2 ± 0.1
38.2 ± 5.4*
 171 ± 33
 133 ± 49
 105 ± 72*,† †
30.9 ± 3.6
 126 (45)
  1.2 (0.1)
40.2 (4.8)*,‡
 270 (77)
§
 138 (67)
¶         
 113 (47)*,† †
Values are mean ± SD. T0: pre-infusion, T1: 5 min after the end of infusion, T2: 3 hr after the end of infusion, T3: 24 hr after the end of infusion. 
PLT: platelet. Between the groups: *P < 0.05 compared to the counterpart of the non-O group. Within the group: 
†P < 0.05 compared to the T1, 
T2, T3. 
‡P < 0.05 compared to T0, T2.
§P < 0.05 compared to T1, T2. 
||P < 0.05 compared to T0, T1, T2. 
¶P < 0.05 compared to T1. **P < 0.05 com-
pared to the T0. 
† †P < 0.05 compared to the T0, T1.347 www.ekja.org
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hematocrit (decreased proportion of hematocrit at T1; non-O 
group 18.6 ± 10.4% vs. O group 20.1 ± 10.6%, P > 0.05) (Fig. 2). 
    aPTT was prolonged in the O group compared to the non-O 
group before HES infusion and throughout the study period (P 
< 0.05) (Fig. 3). 
    Other coagulation profiles did not different between the two 
groups. For the time dependent changes, platelet and fibrin-
ogen decreased at T1. Fibrinogen restored at T3, but platelets 
did not restored during the first 24 h in both groups. PT and 
VWF remained stable during the study period (Table 2).
    There were no differences in the TEG results between the 
groups. For the time dependent changes of TEG variables, 
reaction time (r) and coagulation time (k) were shortened and 
the alpha angle and coagulation index (CI) increased at T2 in 
both groups (Table 3).
    The total amount of blood loss and transfusion was not diffe-
rent between the two groups (Table 4).
Discussion
    Blood type O patients showed decreased factor VIII and 
increased aPTT compared to the non-O patients from T0, 
and transient further deterioration shortly after HES infusion 
made factor VIII and aPTT off the normal range in blood type 
Fig. 2. Comparison of proportional changes of hematocrit and Factor 
VIII after HES infusion at T1. There were no differences between 
hematocrit and Factor VIII in both groups. Error bars are SD.
Fig. 3. aPTT was prolonged in the O group compared to the non-O 
group before HES infusion and throughout the study period. T0: pre-
infusion, T1: 5 min after infusion, T2: 3 hr after infusion, T3: 24 hr 
after the end of infusion. *P < 0.05 between non-O and O groups. 
Error bars are SD.
Table 3. Thromboelastography
Non-O O
T0 T1 T2 T0 T1 T2
R (min)
K (min)
Ma (mm)
Angle (deg)
Ly30 (%)
Ly60 (%)
Index
  13.8 ± 5.5
    6.7 ± 2.9
  49.4 ± 4.7
  35.6 ± 9.0
    3.8 ± 5.6
    9.6 ± 9.9
-1.0 ± 1.5
  11.7 ± 5.5 
    5.7 ± 2.6
  45.8 ± 7.5
†
  38.7 ± 11.5
    5.0 ± 11.3
  10.4 ± 15.0
-1.1 ± 1.7
    8.4 ± 2.3*
    4.6 ± 2.8*
  47.7 ± 6.7
  47.3 ± 9.9*
    7.8 ± 11.8
  14.7 ± 18.0
-0.3 ± 1.2*
  12.5 ± 3.4
    6.3 ± 2.1
  49.4 ± 5.6
  36.3 ± 8.7
    3.5 ± 5.4
    9.2 ± 9.5
-0.9 ± 1.0
  11.3 ± 2.9
    5.6 ± 2.4
  47.8 ± 6.8
  40.3 ± 9.7
    2.2 ± 1.5
    6.6 ± 3.0
-0.8 ± 1.3
   8.9 ± 2.3*
   4.7 ± 1.3
†
 46.9 ± 8.0
 43.3 ± 6.7*
   7.3 ± 13.6
 16.7 ± 20.5
-0.4 ± 1.4
Values are mean ± SD. There were no differences between the non-O and O groups. T0: pre-infusion, T1: 5 min after infusion, T2: 3 hr after infu-
sion. Within the groups: *P < 0.05 compared to T0 and T1. 
†P < 0.05 compared to T0. 
Table 4. Blood Loss
Non-O
(n = 34)
O
(n = 20)
Blood loss (ml)
    Total
    Intraop
    Postop
Red blood cell tansfusion (ml)
    Total              Number
                            Amount
    Intraop         Number
                            Amount
    Postop          Number
                            Amount
1,379 ± 593
1,241 ± 578
137 ± 96
11 
843 ± 358
3 
533 ± 185
10 
768 ± 270
1,677 ± 961
1,561 ± 934
116 ± 95
7 
1,143 ± 736
5 
1,152 ± 834
3
747 ± 185
Values are mean SD. There were no differences between the non-O 
and O groups. Number: number of patients. Intraop: intraoperative, 
Postop: from the end of operation to the postoperative 24 hours. 348 www.ekja.org
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O patients. However, most coagulation factors were rapidly 
recovered and blood loss and the amount of transfusion were 
not different between the two groups.
    The underlying mechanisms of decreased factor VIII in 
the blood type O are not clear. Each blood group has specific 
antigens (A, B, and H determinants) and the only circulating 
plasma glycoproteins expressing N-linked ABH antigens are 
factor VIII/VWF and α 2-macroglobulin [13,14]. O’Donell et 
al.[8] suggested that increased clearance is the underlying 
mechanism for low factor VIII levels in the O blood group 
because factor VIII that expresses H antigen is removed from 
circu  lation more rapidly via distinct hepatic receptors that 
metabolize the terminal fucose of H antigen.
    HES can induce coagulopathy due to inhibition of endothelial 
cell activation [2], reduced release of factor VIII/VWF [3], and 
impairment of platelet function and fibrin polymerization [4,5]. 
The inhibitory mechanisms involve forming a mechanical 
barrier over the cell surface or binding to coagulation factors by 
colloid macromolecules [2,15-17].
    According to our results, factor VIII was lower in the blood 
type O patients from the start, and HES infusion transiently 
further decreased factor VIII which fell below the normal range 
in the O group. aPTT assesses the function of all coagulation 
factors, except factor VII and XIII, and is a good indicator of 
factor VIII. However, the proportional change of factor VIII and 
the approximate degree of hemodilution after HES infusion 
were similar regardless of blood type (Fig. 2). From this result, 
we assumed that the decrease of factor VIII by 15 ml/kg of HES 
is mainly due to hemodilution and not related to the inhibition 
of factor VIII out of proportion by O blood type. 
    There have been few studies dealing coagulopathy after 
HES infusion according to the blood types [10,18]. One study 
examined the hemostatic effect of 6% HES in patients under-
going abdominal surgery [18]. HES was infused according to 
blood loss, hemodynamic variables and duration of surgery 
up to 30 ml/kg and the mean speed of administration was 10 
ml/kg/h like ours. Most of the results were in line with our 
study, however, the decreases of factor VIII and VWF after 
HES infusion were more pronounced than the decrease of the 
hematocrit. The amount of HES and methods of administration 
seem to have affected the results. Factor VIII, VWF, and variables 
of TEG stayed within the normal ranges in this study [18]. The 
other study conducted acute normovolemic hemodilution 
(ANH) with HES in patients undergoing various levels of spine 
surgery [10]. In this case, the proportional decrease of factor VIII 
and VWF 30 minutes after ANH was also beyond that expected 
from hemodilution alone and they fell below the normal range 
in the O group. Considering all these results, speed and amount 
both seem to be important to determine the effect of HES 
infusion on coagulation factors with possibly more weight on 
the speed. Fifteen ml/kg of HES infused at a rate of 10 ml/kg/
h did not produce significant coagulation abnormality in the O 
blood types in our study. 
    In the current study, we searched a 24 hour-effect of HES 
infusion. Infusion of 15 ml/kg of HES decreased platelet, 
fibrinogen, and factor VIII at T1. Platelet remained decreased 
throug  hout the study period. Fibrinogen remained decreased 
until T2 and restored to preinfusion level at T3. Factor VIII 
rebounded more than T0 level at T2 and T3. The net hemostatic 
effect of these changes in coagulation factors is hard to grasp. 
In the view point of TEG which assesses overall hemostasis, 
coagulation was maintained at T1 and enhanced at T2 in 
both groups without between-group differences (Table 3). 
Hemodilution decreases antithrombin III more than thrombin 
and facilitates coagulation [19-21], and hemodilution induced 
hypercoagulation is represented by a shortened r and k in 
TEG [22,23]. Therefore, enhancement of coagulation by hemo-
dilution with HES might have counteracted the decrease of 
coagulation factors at T1. Increased coagulation at T2 in TEG 
in both groups seems to be related to surgical stress induced 
hypercoagulation [24].
    The amount of blood loss was not different between the O and 
non-O blood types in the current study. Previous two studies 
also reported no difference in blood loss [10,18]. The reason 
might be that hemodilution counteracted transient decrease 
of coagulation factors after HES infusion. Secondly, most 
coagulation factors can be easily synthesized from liver and can 
be rapidly released from endothelium and platelets to replace 
losses [25-27]. Thirdly, only 30-50% of factor VIII is known to be 
required for adequate hemostasis during surgery [26,28]. Low 
factor VIII alone, therefore, would unlikely cause difference in 
blood loss in the O blood type. In our study, other coagulation 
factors and TEG variables were not different between the two 
groups. 
    Besides these factors, there are other factors that determine 
coagulation status and bleeding. During surgery, there are 
major disturbances in coagulation and inflammatory systems 
because of hemorrhage/hemodilution, blood transfusion, 
tissue injury, and surgical stresses. In the presence of massive 
hemorrhage and severe hemodilution, the initiation of 
thrombin generation is delayed by reduced Factor VII, and the 
propagation is reduced by the gross reduction of procoagulatant 
serine protease zymogens and accelerators. Allogeneic blood 
transfusions increase thrombin generation and hemostasis. 
Surgical patients have varied degrees of vascular injury. Acute 
inflammatory responses associated with vascular injury often 
result in elevated cytokines, platelet count, fibrinogen, and 
VWF-Factor VIII levels over the normal limit. Tissue injury 
promotes procoagulant activity and inflammation [29]. All 
these factors might have influenced final coagulation status and 349 www.ekja.org
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blood loss. 
    In the current study, we used 15 ml/kg of Voluven (Voluven
Ⓡ, 
Fresenius Kabi, Germany) and showed no detrimental effect 
of HES on blood loss in the O blood type. However, higher 
volumes or different types of HES might bring different results 
[30]. Therefore, further studies are needed to confirm the 
maximum volume that can be safely administered or the effect 
of different types of HES on O blood type patients.
    In conclusion, blood type O patients showed decreased factor 
VIII and increased aPTT compared to the non-O patients from 
the beginning, and transient further deterioration shortly after 
15 ml/kg of Voluven infusion. However, other coagulation 
factors and TEG variables were not different, neither the 
amount of blood loss between the two groups. Therefore, 15 ml/
kg of Voluven does not further increase the risk of bleeding in 
the blood type O patients and can be safely administered during 
PLIF.
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